2-(3-Fluorophenyl)-3-pyridin-4-ylimidazo[4,5-b]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-Fluorophenyl)-3-pyridin-4-ylimidazo[4,5-b]pyridine
• 化学式: C₁₇H₁₁FN₄
• 分子量: 290.29
• InChiKey: GLZGWWUGCBKGIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES
  申请人：Eisai Co., Ltd.

  公开号：EP1054012A1

  公开（公告）日：2000-11-22

  The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonistic action. A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof has an adenosine A2 receptor antagonistic action and is useful for prevention or therapy of diabetes mellitus and diabetic complications. In addition, adenosine A2 receptor antagonists having different structures from those of the compounds described above, for example KW6002, are also effective for prevention or therapy of diabetes mellitus and diabetic complications. In the formula, W is -CH2CH2-, -CH=CH- or -C≡C-; R1 is: (in the formula, X is hydrogen atom, hydroxyl group, a lower alkyl group, a lower alkoxy group, etc.; and R5 and R6 are the same as or different from each other and each represents hydrogen atom, a lower alkyl group, a cycloalkyl group, etc.) and the like; R2 is an amino group, etc. which may be substituted with a lower alkyl group, etc.; R3 is a cycloalkyl group, an optionally substituted aryl group, etc.; and R4 is a lower alkyl group, etc.

  本发明提供了一种基于腺苷 A2 受体拮抗作用的新型糖尿病和糖尿病并发症预防或治疗剂。 由式（I）代表的嘌呤化合物、其药理上可接受的盐或其水合物具有腺苷 A2 受体拮抗作用，可用于预防或治疗糖尿病和糖尿病并发症。此外，与上述化合物结构不同的腺苷 A2 受体拮抗剂，例如 KW6002，也可有效预防或治疗糖尿病和糖尿病并发症。 式中，W为-CH2CH2-、-CH=CH-或-C≡C-；R1为： (式中，X 是氢原子、羟基、低级烷基、低级烷氧基等；R5 和 R6 彼此相同或不同，各自代表氢原子、低级烷基、环烷基等）等；R2 是可被低级烷基等取代的氨基等；R3 是环烷基、任选取代的芳基等；R4 是低级烷基等。
• Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus
  申请人：Eisai Co. Ltd

  公开号：EP1300147A1

  公开（公告）日：2003-04-09

  The present invention relates to the use of A2 receptor antagonists and their pharmacologically acceptable salts or hydrates for preparing medicaments for preventing or treating diabetes mellitus or diabetic complications, and for preparing improving agents for impaired glucose tolerance, potentiating agent for insulin sensitivity or medicaments for preventing or treating obesity.

  本发明涉及 A2 受体拮抗剂及其药理学上可接受的盐或水合物用于制备预防或治疗糖尿病或糖尿病并发症的药物，以及用于制备改善糖耐量受损的药物、提高胰岛素敏感性的药物或预防或治疗肥胖症的药物。